Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Los Angeles, CA
NPI: 1063558682Primary Employer
Cedars-Sinai Medical Care Foundation
cedars-sinai.org
HQ Phone
Get M.D. Ani's Phone Numberphone_androidMobile
Get M.D. Ani's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 36415Insertion of needle into vein for collection of blood sample | 183 | 408 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 175 | 501 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 166 | 881 |
| 4 | 80053Blood test, comprehensive group of blood chemicals | 158 | 812 |
| 5 | 83615Lactate dehydrogenase (enzyme) level | 141 | 497 |
Pembrolizumab for the treatment of non-small-cell lung cancer.
Authors: Gregory Lubiniecki, Amita Patnaik, Joseph Eder, Naiyer Rizvi, Edward Garon, Matthew Hellmann, Omid Hamid, Charu Aggarwal
Journal: N Engl J Med
Publication Date: 2015-04-19
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Authors: Jamie Chaft, Naiyer Rizvi
Publication Date: 2015-10-14
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Authors: Jason Luke, Anthony Olszanski, Lance Leopold, Thomas Gajewski, Jeffrey Wasser, Todd Bauer, Omid Hamid, Tara Mitchell, Emmett Schmidt
Publication Date: 2018-09-29
Lead Sponsor: GlaxoSmithKline
Collaborators: iTeos Belgium SA
Intervention / Treatment: DRUG: Docetaxel, DRUG: Ipilimumab, DRUG: Dostarlimab, DRUG: GSK6097608, DRUG: Feladilimab, DRUG: GSK4428859A
Lead Sponsor: Arcus Biosciences, Inc.
Collaborators: Gilead Sciences
Intervention / Treatment: DRUG: Zimberelimab, DRUG: Domvanalimab
Lead Sponsor: GlaxoSmithKline
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Docetaxel, DRUG: Pembrolizumab, DRUG: Pemetrexed, DRUG: Bintrafusp alfa, DRUG: Dostarlimab, DRUG: GSK3174998, DRUG: Cobolimab, DRUG: feladilimab (GSK3359609), DRUG: Paclitaxel plus Carboplatin, DRUG: Gemcitabine plus Carboplatin, DRUG: Fluorouracil (5-FU) plus carboplatin or cisplatin